The Department of Cardiology, Amrita Hospital, Faridabad, in collaboration with Novartis, organized a Continuing Medical Education (CME) program on 28th October 2025 at Seminar Hall 1, Amrita Hospital. The session, titled "Unveiling the Power of Inclisiran for Lipid Lowering,” focused on the latest advancements in the management of dyslipidemia and cholesterol control through the novel therapeutic agent, Inclisiran.
The program was held from 4:00 pm to 5:00 pm and brought together doctors and specialists from various departments, including the Cardiology, Nephrology, Neurology, and Anesthesiology teams etc, as well as senior residents from other departments from Amrita Hospital, Faridabad. The CME aimed to enhance interdisciplinary understanding of new treatment approaches for lipid disorders and their implications for long-term cardiovascular health.
The session commenced with a lamp-lighting ceremony, symbolizing the pursuit of knowledge and healing. The inaugural lighting was performed by Dr. Vivek Chaturvedi, Professor and Head, Department of Cardiology, along with members of the Novartis team. The ceremony reflected the collaborative spirit between academia and the pharmaceutical industry in advancing patient care and research.
Dr. Vivek Chaturvedi, a leading authority in cardiovascular medicine, served as the guest speaker for the session. He delivered an insightful lecture on the topic “The Inclisiran Advantage,” emphasizing the emerging role of Inclisiran in lipid management.
During his talk, Dr. Chaturvedi highlighted the clinical efficacy, dosing convenience, and long-term safety of Inclisiran, which distinguishes it from conventional lipid-lowering therapies. He discussed the importance of maintaining optimal lipid levels to prevent atherosclerotic cardiovascular diseases and how Inclisiran’s biannual dosing regimen could improve patient adherence and outcomes. The discussion also covered current research data, ongoing clinical trials, and practical insights on integrating Inclisiran into standard treatment protocols for patients with dyslipidemia.
The audience included faculty members, residents, and consultants who engaged in an interactive Q&A session. Participants raised pertinent questions on patient selection, cost-effectiveness, and the future potential.
The CME concluded with a vote of thanks, acknowledging Dr. Vivek Chaturvedi for his comprehensive session, the Novartis team for their partnership, and all participating departments for their enthusiastic involvement. The event was highly appreciated for its educational value and relevance to current clinical practice, especially in light of the increasing burden of dyslipidemia and cardiovascular disease in India.
The program successfully reinforced the importance of interdisciplinary learning and the adoption of evidence-based innovations to improve patient outcomes. With discussions on cutting-edge therapies like Inclisiran, the CME reflected Amrita Hospital’s continued dedication to fostering academic excellence and advancing the standards of cardiac care.
